Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


01.10.2018

1 AJNR Am J Neuroradiol
2 J Neuroimmunol
1 J Neurol
1 J Neurol Neurosurg Psychiatry
1 J Neurol Sci
1 Lancet
3 Lancet Neurol
1 Mult Scler
1 Neurologia


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJNR Am J Neuroradiol

  1. FORSLIN Y, Bergendal A, Hashim F, Martola J, et al
    Detection of Leukocortical Lesions in Multiple Sclerosis and Their Association with Physical and Cognitive Impairment: A Comparison of Conventional and Synthetic Phase-Sensitive Inversion Recovery MRI.
    AJNR Am J Neuroradiol. 2018 Sep 27. pii: ajnr.A5815. doi: 10.3174/ajnr.A5815.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  2. MCWILLIAM O, Sellebjerg F, Marquart HV, von Essen MR, et al
    B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTalpha and TGFbeta1 response.
    J Neuroimmunol. 2018 Sep 7. pii: S0165-5728(18)30276.
    PubMed     Text format     Abstract available

  3. JAFARZADEH A, Nemati M
    Therapeutic potentials of ginger for treatment of Multiple sclerosis: A review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties.
    J Neuroimmunol. 2018;324:54-75.
    PubMed     Text format     Abstract available


    J Neurol

  4. PROSPERINI L, Annovazzi P, Boffa L, Buscarinu MC, et al
    No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    J Neurol. 2018 Sep 26. pii: 10.1007/s00415-018-9070.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  5. PALACE J, Duddy M, Lawton M, Bregenzer T, et al
    Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.
    J Neurol Neurosurg Psychiatry. 2018 Sep 21. pii: jnnp-2018-318360.
    PubMed     Text format     Abstract available


    J Neurol Sci

  6. HEALY BC, Glanz BI, Zurawski JD, Mazzola M, et al
    Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
    J Neurol Sci. 2018;394:127-131.
    PubMed     Text format     Abstract available


    Lancet

  7. METZ LM, Liu WQ
    Effective treatment of progressive MS remains elusive.
    Lancet. 2018;391:1239-1240.
    PubMed     Text format    


    Lancet Neurol

  8. ROCCA MA, Barkhof F, De Luca J, Frisen J, et al
    The hippocampus in multiple sclerosis.
    Lancet Neurol. 2018;17:918-926.
    PubMed     Text format     Abstract available

  9. STYS PK
    Myelocortical multiple sclerosis: a new disease subtype?
    Lancet Neurol. 2018;17:832-834.
    PubMed     Text format    

  10. FEINSTEIN A
    The hippocampus and behaviour in multiple sclerosis.
    Lancet Neurol. 2018;17:837-839.
    PubMed     Text format    


    Mult Scler

  11. BOSE G, Atkins HL, Bowman M, Freedman MS, et al
    Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
    Mult Scler. 2018 Sep 25:1352458518802544. doi: 10.1177/1352458518802544.
    PubMed     Text format     Abstract available


    Neurologia

  12. RAMIO-TORRENTA L, Alvarez-Cermeno JC, Arroyo R, Casanova-Estruch B, et al
    A guide to treating gait impairment with prolonged-release fampridine (Fampyra((R))) in patients with multiple sclerosis.
    Neurologia. 2018;33:327-337.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: